Please login to the form below

Not currently logged in
Email:
Password:

Swedish Orphan Biovitrum

This page shows the latest Swedish Orphan Biovitrum news and features for those working in and with pharma, biotech and healthcare.

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

Approval adds to growing US portfolio. Swedish Orphan Biovitrum (Sobi) has the US approval it sought for Gamifant, an ultra-rare disease therapy it licensed from Novimmune for $452m a few ... In Europe, emapalumab has been granted orphan designation and

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions. ... The UK, in common with many developed markets, has large numbers of products that, while they do have a licence and are currently available, are rarely

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum.  Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved)  .  40. All deals are worldwide unless otherwise noted – see below:.   .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Say Communications

    Roche Diabetes Care. Swedish Orphan Biovitrum. Target Ovarian Cancer. Trudell Medical.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics